Elevated heparanase expression by myeloma cells enhances their resistance to both bortezomib and melphalan and this resistance is reversedin vivo when mice are treated with the heparanase inhibitor Roneparstat25. This evidence concerns the gene HPSE and plasma cell myeloma.